Literature DB >> 33288635

Evidence-Based Guidelines Should Be Used To Inform COVID-19 Management.

Thomas L Holland1,2.   

Abstract

Entities:  

Keywords:  COVID-19

Mesh：

Substances：

Year:  2021        PMID： 33288635      PMCID： PMC8092555          DOI： 10.1128/AAC.02501-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.

LETTER

A recent commentary by McCullough (1) includes a recommended coronavirus disease (COVID) treatment algorithm that is outdated and parts of which are contradicted by high-quality trial data. Specifically, hydroxychloroquine has shown no benefit in a large number of trials, including in nonhospitalized patients (2, 3). Consensus guidelines from the National Institutes of Health and the Infectious Diseases Society of America recommend against the use of hydroxychloroquine with or without azithromycin (4, 5). Based on the RECOVERY trial, steroids also should not be used in patients who do not require supplemental oxygen (6). Dr. McCullough is correct that large conclusive trials are most helpful in determining a COVID treatment algorithm; now that we have a number of these trials, his proposed algorithm should not be presented or followed.
  4 in total

1.  Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial.

Authors:  Oriol Mitjà; Marc Corbacho-Monné; Maria Ubals; Cristian Tebé; Judith Peñafiel; Aurelio Tobias; Ester Ballana; Andrea Alemany; Núria Riera-Martí; Carla A Pérez; Clara Suñer; Pep Laporte; Pol Admella; Jordi Mitjà; Mireia Clua; Laia Bertran; Maria Sarquella; Sergi Gavilán; Jordi Ara; Josep M Argimon; Jordi Casabona; Gabriel Cuatrecasas; Paz Cañadas; Aleix Elizalde-Torrent; Robert Fabregat; Magí Farré; Anna Forcada; Gemma Flores-Mateo; Esteve Muntada; Núria Nadal; Silvia Narejos; Aroa Nieto; Nuria Prat; Jordi Puig; Carles Quiñones; Juliana Reyes-Ureña; Ferran Ramírez-Viaplana; Lidia Ruiz; Eva Riveira-Muñoz; Alba Sierra; César Velasco; Rosa Maria Vivanco-Hidalgo; Alexis Sentís; Camila G-Beiras; Bonaventura Clotet; Martí Vall-Mayans
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

2.  Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial.

Authors:  Caleb P Skipper; Katelyn A Pastick; Nicole W Engen; Ananta S Bangdiwala; Mahsa Abassi; Sarah M Lofgren; Darlisha A Williams; Elizabeth C Okafor; Matthew F Pullen; Melanie R Nicol; Alanna A Nascene; Kathy H Hullsiek; Matthew P Cheng; Darlette Luke; Sylvain A Lother; Lauren J MacKenzie; Glen Drobot; Lauren E Kelly; Ilan S Schwartz; Ryan Zarychanski; Emily G McDonald; Todd C Lee; Radha Rajasingham; David R Boulware
Journal:  Ann Intern Med       Date:  2020-07-16       Impact factor: 25.391

3.  Dexamethasone in Hospitalized Patients with Covid-19.

Authors:  Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray
Journal:  N Engl J Med       Date:  2020-07-17       Impact factor: 91.245

4.  Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).

Authors:  Peter A McCullough
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.